Investors

Webcast ImageWebcast
Q4 2016 Aeglea Biotherapeutics, Inc. Earnings Conference Call (Live)
03/23/17 at 4:30 p.m. ET
Q4 2016 Aeglea Biotherapeutics, Inc. Earnings Conference Call
Thursday, March 23, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

Stock Information

AGLE (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.44
Change (%) Stock is Down 0.27 (3.50%)
Volume48,932
As of 03/23/17 1:46 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: AGLE.O.  Currently trading at $7.44 with a 52 week high of $12.75 and a 52 week low of $3.66.

Recent News

More >>
03/23/17

Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting

AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancers

Read More

03/17/17

Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23

Company to host conference call and webcast to provide business update and review topline Phase 1 Arginase I deficiency clinical results AUSTIN, Texas, March 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology

Read More

02/28/17

Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism

AUSTIN, Texas, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer,

Read More

Upcoming Events

More >>
DateTitle
03/23/17
Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
03/23/17 4:30 p.m. ET
Q4 2016 Aeglea Biotherapeutics, Inc. Earnings Conference Call